Skip to main content

Advertisement

Table 2 Model baseline population parameters

From: Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

Parameter Values and  % of patients Standard errora Distributions used in the PSA
Gender    
 Female (%) 32.0 % 1.15 % Beta
 Mean age (years) 63.3 0.1 Normal
BMI    
 Low (%) 10.4 % 0.84 % Beta
 Medium (%) 65.1 %
 High (%) 24.5 % 1.02 % Beta
Any CVD comorbidity (%) 43.5 % 1.13 % Beta
Without comorbidity (%) 56.5 %
Any other comorbidity (%) 77.3 % 1.07 % Beta
History of exacerbation, 1 or more (%) 46.2 % 1.21 % Beta
mMRC score ≥2 (%) 100.0 %  
Current smokers (%) 49.0 % 1.16 % Beta
Height (cm) 169.0 0.1 Normal
Fibrinogen (µg/mL) 458.8 102.4 Gamma
Number of exacerbations in prior year 0.50 0.01 Gamma
Proportion of prior exacerbations that are severe 20.0   Gamma
Starting SGRQ score 49.1 0.5 Normal
Starting FEV1 %p (%) 47.7 % 0.2 % Beta
6-min walk distance (m) 378.3 2.9 Normal
  1. BMI body mass index, CVD cardiovascular disease, ECLIPSE Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints, FEV1%p forced expiratory volume in 1 s percent predicted, mMRC modified Medical Research Council dyspnoea scale, PSA probabilistic sensitivity analysis, SE standard error, SGRQ St. George’s Respiratory Questionnaire
  2. a SE Calculated or assumed based on availability of data